Summary
Ophthalmology disorders are associated with the eyes and visual system. If left untreated, serious long-term co-morbidities such as diabetes, and particularly blindness, can arise. Although there are a number of treatments approved in ophthalmology, there are currently no curative therapies for any of these indications. In particular, there are strong unmet needs within age-related macular degeneration and glaucoma, which can lead to blindness if not adequately treated.
Although there is a high degree of failure and uncertainty within the R&D of pharmaceuticals, there is a great deal of interest in ophthalmology development. Overall, there are over 700 products in active development in the ophthalmology therapy area, making it one of the largest therapy area pipelines.
Although two thirds of products in development for ophthalmology disorders are at the Discovery or Preclinical stage of development, the number of drugs in the pipeline is very high, creating strong potential for a blockbuster drug to enter the market.
The report provides comprehensive information on the pipeline development landscape for glaucoma, age-related macular degeneration, diabetic retinopathy, diabetic macular edema and keratoconjunctivitis sicca (dry eye), from Discovery through to the Pre-Registration stage. This includes an analysis of products by stage of development, molecular target, mechanism of action (MoA), route of administration (RoA) and molecule type. A list of all products in development is provided, including dormant and discontinued projects. Finally, the report provides an overview of key players involved in the development of products in this area, and outlines recent updates and press releases in the field.
Scope
- Which companies are the most active within the pipeline for ophthalmology?
- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
- What are the most important R&D milestones and data publications to have occurred in ophthalmology?
Reasons to buy
- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication.
- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each.
- Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these.
- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration.
'
1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 5
1.2 List of Figures 13
2 Introduction 15
2.1 Ophthalmology Therapeutics Report Coverage 15
3 Therapeutics Development by Stage 18
3.1 Age Related Macular Degeneration 18
3.2 Diabetic Retinopathy 20
3.3 Diabetic Macular Edema 22
3.4 Keratoconjunctivitis sicca (Dry Eye) 24
3.5 Glaucoma 26
4 Therapeutics under Development by Companies 28
4.1 Age Related Macular Degeneration 28
4.2 Diabetic Retinopathy 39
4.3 Diabetic Macular Edema 42
4.4 Keratoconjunctivitis sicca (Dry Eye) 46
4.5 Glaucoma 50
5 Therapeutics under Investigation by Universities/Institutes 56
5.1 Age Related Macular Degeneration 56
5.2 Diabetic Retinopathy 57
5.3 Diabetic Macular Edema 57
5.4 Keratoconjunctivitis sicca (Dry Eye) 58
5.5 Glaucoma 58
6 Pipeline Products Glance 60
6.1 Age Related Macular Degeneration 60
6.2 Diabetic Retinopathy 64
6.3 Diabetic Macular Edema 66
6.4 Keratoconjunctivitis sicca (Dry Eye) 69
6.5 Glaucoma 72
7 Products under Development by Companies 76
7.1 Age Related Macular Degeneration 76
7.2 Diabetic Retinopathy 90
7.3 Diabetic Macular Edema 94
7.4 Keratoconjunctivitis sicca (Dry Eye) 98
7.5 Glaucoma 102
8 Products under Investigation by Universities/Institutes 108
8.1 Age Related Macular Degeneration 108
8.2 Diabetic Retinopathy 109
8.3 Diabetic Macular Edema 110
8.4 Keratoconjunctivitis sicca (Dry Eye) 110
8.5 Glaucoma 111
9 Companies Involved in Therapeutics Development 112
9.1 Age Related Macular Degeneration 112
9.2 Diabetic Retinopathy 173
9.3 Diabetic Macular Edema 194
9.4 Keratoconjunctivitis sicca (Dry Eye) 213
9.5 Glaucoma 231
10 Therapeutics Assessment 290
10.1 Age Related Macular Degeneration 290
10.2 Diabetic Retinopathy 310
10.3 Diabetic Macular Edema 322
10.4 Keratoconjunctivitis sicca (Dry Eye) 335
10.5 Glaucoma 353
11 Recent Pipeline Updates 373
11.1 Age Related Macular Degeneration 373
11.2 Diabetic Retinopathy 496
12 Dormant Projects 541
12.1 Age Related Macular Degeneration 541
12.2 Diabetic Retinopathy 555
12.3 Diabetic Macular Edema 561
12.4 Keratoconjunctivitis sicca (Dry Eye) 564
12.5 Glaucoma 570
13 Discontinued Products 577
13.1 Age Related Macular Degeneration 577
13.2 Diabetic Retinopathy 578
13.3 Diabetic Macular Edema 579
13.4 Keratoconjunctivitis sicca (Dry Eye) 580
13.5 Glaucoma 581
14 Product Development Milestones 583
14.1 Age Related Macular Degeneration 583
14.2 Diabetic Retinopathy 590
14.3 Diabetic Macular Edema 597
14.4 Keratoconjunctivitis sicca (Dry Eye) 607
14.5 Glaucoma 618
15 Appendix 632
15.1 Research Methodology 632
15.2 Secondary Research 632
15.3 Contact Us 633
15.4 Disclaimer 633
1.1 List of Tables
Table 1: Number of Products under Development for Age Related Macular Degeneration 18
Table 2: Number of Products under Development for Age Related Macular Degeneration – Comparative Analysis 19
Table 3: Number of Products under Development for Diabetic Retinopathy 20
Table 4: Number of Products under Development for Diabetic Retinopathy – Comparative Analysis 21
Table 5: Number of Products under Development for Diabetic Macular Edema 22
Table 6: Number of Products under Development for Diabetic Macular Edema – Comparative Analysis 23
Table 7: Number of Products under Development for Keratoconjunctivitis sicca (Dry Eye) 24
Table 8: Number of Products under Development for Keratoconjunctivitis sicca (Dry Eye) – Comparative Analysis 25
Table 9: Number of Products under Development for Glaucoma, H2 2016 26
Table 10: Number of Products under Development for Glaucoma – Comparative Analysis, H2 2016 27
Table 11: Number of Products under Development by Companies 29
Table 12: Number of Products under Development by Companies (Contd..1) 30
Table 13: Number of Products under Development by Companies (Contd..2) 31
Table 14: Number of Products under Development by Companies (Contd..3) 32
Table 15: Number of Products under Development by Companies (Contd..4) 33
Table 16: Number of Products under Development by Companies (Contd..5) 34
Table 17: Number of Products under Development by Companies (Contd..6) 35
Table 18: Number of Products under Development by Companies (Contd..7) 36
Table 19: Number of Products under Development by Companies (Contd..8) 37
Table 20: Number of Products under Development by Companies (Contd..9) 38
Table 21: Number of Products under Development by Companies 39
Table 22: Number of Products under Development by Companies (Contd..1) 40
Table 23: Number of Products under Development by Companies (Contd..2) 41
Table 24: Number of Products under Development by Companies 43
Table 25: Number of Products under Development by Companies (Contd..1) 44
Table 26: Number of Products under Development by Companies (Contd..2) 45
Table 27: Number of Products under Development by Companies 47
Table 28: Number of Products under Development by Companies (Contd..1) 48
Table 29: Number of Products under Development by Companies (Contd..2) 49
Table 30: Number of Products under Development by Companies, H2 2016 51
Table 31: Number of Products under Development by Companies, H2 2016 (Contd..1) 52
Table 32: Number of Products under Development by Companies, H2 2016 (Contd..2) 53
Table 33: Number of Products under Development by Companies, H2 2016 (Contd..3) 54
Table 34: Number of Products under Development by Companies, H2 2016 (Contd..4) 55
Table 35: Number of Products under Investigation by Universities/Institutes 56
Table 36: Number of Products under Investigation by Universities/Institutes 57
Table 37: Number of Products under Investigation by Universities/Institutes 57
Table 38: Number of Products under Investigation by Universities/Institutes 58
Table 39: Number of Products under Investigation by Universities/Institutes, H2 2016 59
Table 40: Comparative Analysis by Late Stage Development 60
Table 41: Comparative Analysis by Clinical Stage Development 61
Table 42: Comparative Analysis by Early Stage Development 62
Table 43: Comparative Analysis by Unknown Stage Development 63
Table 44: Comparative Analysis by Clinical Stage Development 64
Table 45: Comparative Analysis by Early Stage Development 65
Table 46: Comparative Analysis by Unknown Stage Development 65
Table 47: Comparative Analysis by Late Stage Development 66
Table 48: Comparative Analysis by Clinical Stage Development 67
Table 49: Comparative Analysis by Early Stage Development 68
Table 50: Comparative Analysis by Unknown Stage Development 68
Table 51: Comparative Analysis by Late Stage Development 69
Table 52: Comparative Analysis by Clinical Stage Development 70
Table 53: Comparative Analysis by Early Stage Development 71
Table 54: Comparative Analysis by Unknown Stage Development 71
Table 55: Comparative Analysis by Late Stage Development, H2 2016 72
Table 56: Comparative Analysis by Clinical Stage Development, H2 2016 73
Table 57: Comparative Analysis by Early Stage Development, H2 2016 74
Table 58: Comparative Analysis by Unknown Stage Development, H2 2016 75
Table 59: Products under Development by Companies 76
Table 60: Products under Development by Companies (Contd..1) 77
Table 61: Products under Development by Companies (Contd..2) 78
Table 62: Products under Development by Companies (Contd..3) 79
Table 63: Products under Development by Companies (Contd..4) 80
Table 64: Products under Development by Companies (Contd..5) 81
Table 65: Products under Development by Companies (Contd..6) 82
Table 66: Products under Development by Companies (Contd..7) 83
Table 67: Products under Development by Companies (Contd..8) 84
Table 68: Products under Development by Companies (Contd..9) 85
Table 69: Products under Development by Companies (Contd..10) 86
Table 70: Products under Development by Companies (Contd..11) 88
Table 71: Products under Development by Companies 90
Table 72: Products under Development by Companies (Contd..1) 91
Table 73: Products under Development by Companies (Contd..2) 92
Table 74: Products under Development by Companies (Contd..3) 93
Table 75: Products under Development by Companies 94
Table 76: Products under Development by Companies (Contd..1) 95
Table 77: Products under Development by Companies (Contd..2) 96
Table 78: Products under Development by Companies 98
Table 79: Products under Development by Companies (Contd..1) 99
Table 80: Products under Development by Companies (Contd..2) 100
Table 81: Products under Development by Companies (Contd..3) 101
Table 82: Products under Development by Companies, H2 2016 102
Table 83: Products under Development by Companies, H2 2016 (Contd..1) 103
Table 84: Products under Development by Companies, H2 2016 (Contd..2) 104
Table 85: Products under Development by Companies, H2 2016 (Contd..3) 105
Table 86: Products under Development by Companies, H2 2016 (Contd..4) 106
Table 87: Products under Development by Companies, H2 2016 (Contd..5) 107
Table 88: Products under Investigation by Universities/Institutes 108
Table 89: Products under Investigation by Universities/Institutes 109
Table 90: Products under Investigation by Universities/Institutes 110
Table 91: Products under Investigation by Universities/Institutes 110
Table 92: Products under Investigation by Universities/Institutes, H2 2016 111
Table 93: Age Related Macular Degeneration – Pipeline by AC Immune SA 112
Table 94: Age Related Macular Degeneration – Pipeline by Achillion Pharmaceuticals, Inc. 112
Table 95: Age Related Macular Degeneration – Pipeline by Aciont Inc. 113
Table 96: Age Related Macular Degeneration – Pipeline by AdAlta Pty Ltd. 113
Table 97: Age Related Macular Degeneration – Pipeline by Adverum Biotechnologies, Inc. 114
Table 98: Age Related Macular Degeneration – Pipeline by Aerie Pharmaceuticals, Inc. 114
Table 99: Age Related Macular Degeneration – Pipeline by Aerpio Therapeutics, Inc. 115
Table 100: Age Related Macular Degeneration – Pipeline by Alimera Sciences, Inc. 115
Table 101: Age Related Macular Degeneration – Pipeline by Alkeus Pharmaceuticals, Inc. 116
Table 102: Age Related Macular Degeneration – Pipeline by Allergan Plc 116
Table 103: Age Related Macular Degeneration – Pipeline by Allinky Biopharma 117
Table 104: Age Related Macular Degeneration – Pipeline by Alteogen Inc. 117
Table 105: Age Related Macular Degeneration – Pipeline by Amakem NV 118
Table 106: Age Related Macular Degeneration – Pipeline by Amarna Therapeutics B.V. 118
Table 107: Age Related Macular Degeneration – Pipeline by Ampio Pharmaceuticals, Inc. 119
Table 108: Age Related Macular Degeneration – Pipeline by Amyndas Pharmaceuticals LLC 119
Table 109: Age Related Macular Degeneration – Pipeline by Apellis Pharmaceuticals, Inc. 120
Table 110: Age Related Macular Degeneration – Pipeline by Apexigen, Inc. 120
Table 111: Age Related Macular Degeneration – Pipeline by Applied Genetic Technologies Corporation 121
Table 112: Age Related Macular Degeneration – Pipeline by Astellas Pharma Inc. 121
Table 113: Age Related Macular Degeneration – Pipeline by Benitec Biopharma Limited 122
Table 114: Age Related Macular Degeneration – Pipeline by BIOCAD 122
Table 115: Age Related Macular Degeneration – Pipeline by Biokine Therapeutics Ltd. 123
Table 116: Age Related Macular Degeneration – Pipeline by BioMAS Ltd. 123
Table 117: Age Related Macular Degeneration – Pipeline by Biomics Biotechnologies Co., Ltd. 124
Table 118: Age Related Macular Degeneration – Pipeline by Biophytis SAS 124
Table 119: Age Related Macular Degeneration – Pipeline by Boehringer Ingelheim GmbH 125
Table 120: Age Related Macular Degeneration – Pipeline by Caladrius Biosciences, Inc. 125
Table 121: Age Related Macular Degeneration – Pipeline by Catalyst Biosciences, Inc. 126
Table 122: Age Related Macular Degeneration – Pipeline by Cell Cure Neurosciences, Ltd. 126
Table 123: Age Related Macular Degeneration – Pipeline by Charlesson LLC. 127
Table 124: Age Related Macular Degeneration – Pipeline by Cipla Ltd. 127
Table 125: Age Related Macular Degeneration – Pipeline by Clanotech AB 128
Table 126: Age Related Macular Degeneration – Pipeline by Clearside BioMedical, Inc. 128
Table 127: Age Related Macular Degeneration – Pipeline by Clonz Biotech Private Limited 129
Table 128: Age Related Macular Degeneration – Pipeline by Coherus BioSciences, Inc. 129
Table 129: Age Related Macular Degeneration – Pipeline by Colby Pharmaceutical Company 130
Table 130: Age Related Macular Degeneration – Pipeline by Crinetics Pharmaceuticals, Inc. 130
Table 131: Age Related Macular Degeneration – Pipeline by Critical Pharmaceuticals Limited 131
Table 132: Age Related Macular Degeneration – Pipeline by Daiichi Sankyo Company, Limited 131
Table 133: Age Related Macular Degeneration – Pipeline by Delenex Therapeutics AG 132
Table 134: Age Related Macular Degeneration – Pipeline by Diffusion Pharmaceuticals Inc. 132
Table 135: Age Related Macular Degeneration – Pipeline by Digna Biotech, S.L. 133
Table 136: Age Related Macular Degeneration – Pipeline by Eleven Biotherapeutics Inc. 133
Table 137: Age Related Macular Degeneration – Pipeline by Elsalys Biotech SAS 134
Table 138: Age Related Macular Degeneration – Pipeline by Exonate Limited 134
Table 139: Age Related Macular Degeneration – Pipeline by F. Hoffmann-La Roche Ltd. 135
Table 140: Age Related Macular Degeneration – Pipeline by Foamix Pharmaceuticals Ltd. 135
Table 141: Age Related Macular Degeneration – Pipeline by Formycon AG 136
Table 142: Age Related Macular Degeneration – Pipeline by Gene Techno Science Co., Ltd. 136
Table 143: Age Related Macular Degeneration – Pipeline by Genentech, Inc. 137
Table 144: Age Related Macular Degeneration – Pipeline by GenSight Biologics S.A. 137
Table 145: Age Related Macular Degeneration – Pipeline by GlaxoSmithKline Plc 138
Table 146: Age Related Macular Degeneration – Pipeline by Grupo Ferrer Internacional, S.A. 138
Table 147: Age Related Macular Degeneration – Pipeline by GTx, Inc. 139
Table 148: Age Related Macular Degeneration – Pipeline by HanAll Biopharma Co., Ltd. 139
Table 149: Age Related Macular Degeneration – Pipeline by Huabo Biopharm Co., Ltd. 140
Table 150: Age Related Macular Degeneration – Pipeline by iCo Therapeutics Inc. 140
Table 151: Age Related Macular Degeneration – Pipeline by Icon Bioscience, Inc. 141
Table 152: Age Related Macular Degeneration – Pipeline by Iconic Therapeutics, Inc. 141
Table 153: Age Related Macular Degeneration – Pipeline by Innovent Biologics, Inc. 142
Table 154: Age Related Macular Degeneration – Pipeline by Intellect Neurosciences, Inc. 142
Table 155: Age Related Macular Degeneration – Pipeline by International Stem Cell Corporation 143
Table 156: Age Related Macular Degeneration – Pipeline by Ionis Pharmaceuticals, Inc. 143
Table 157: Age Related Macular Degeneration – Pipeline by Jeil Pharmaceutical Co., Ltd. 144
Table 158: Age Related Macular Degeneration – Pipeline by Johnson & Johnson 145
Table 159: Age Related Macular Degeneration – Pipeline by Kadmon Corporation, LLC 146
Table 160: Age Related Macular Degeneration – Pipeline by Kala Pharmaceuticals, Inc. 146
Table 161: Age Related Macular Degeneration – Pipeline by Kodiak Sciences, Inc. 147
Table 162: Age Related Macular Degeneration – Pipeline by LeadArtis S.L. 147
Table 163: Age Related Macular Degeneration – Pipeline by M's Science Corporation 148
Table 164: Age Related Macular Degeneration – Pipeline by Mabion SA 148
Table 165: Age Related Macular Degeneration – Pipeline by MacuCLEAR, Inc. 149
Table 166: Age Related Macular Degeneration – Pipeline by Mitotech S.A. 149
Table 167: Age Related Macular Degeneration – Pipeline by Mitsubishi Tanabe Pharma Corporation 150
Table 168: Age Related Macular Degeneration – Pipeline by Navigen Pharmaceuticals, Inc. 150
Table 169: Age Related Macular Degeneration – Pipeline by Navya Biologicals Pvt Ltd 151
Table 170: Age Related Macular Degeneration – Pipeline by Neovacs SA 151
Table 171: Age Related Macular Degeneration – Pipeline by Neumedicines Inc. 152
Table 172: Age Related Macular Degeneration – Pipeline by Neuroptis Biotech 152
Table 173: Age Related Macular Degeneration – Pipeline by Neurotech Pharmaceuticals, Inc. 153
Table 174: Age Related Macular Degeneration – Pipeline by Novartis AG 153
Table 175: Age Related Macular Degeneration – Pipeline by Ocular Therapeutix, Inc. 154
Table 176: Age Related Macular Degeneration – Pipeline by Ohr Pharmaceutical Inc. 154
Table 177: Age Related Macular Degeneration – Pipeline by Omeros Corporation 155
Table 178: Age Related Macular Degeneration – Pipeline by Ophthotech Corp. 155
Table 179: Age Related Macular Degeneration – Pipeline by Orphagen Pharmaceuticals, Inc. 156
Table 180: Age Related Macular Degeneration – Pipeline by Oxford BioMedica Plc 156
Table 181: Age Related Macular Degeneration – Pipeline by PanOptica, Inc. 157
Table 182: Age Related Macular Degeneration – Pipeline by Pfenex Inc. 157
Table 183: Age Related Macular Degeneration – Pipeline by Pfizer Inc. 158
Table 184: Age Related Macular Degeneration – Pipeline by Precision Ocular Ltd 158
Table 185: Age Related Macular Degeneration – Pipeline by Promedior, Inc. 159
Table 186: Age Related Macular Degeneration – Pipeline by pSivida Corp. 159
Table 187: Age Related Macular Degeneration – Pipeline by QLT Inc. 160
Table 188: Age Related Macular Degeneration – Pipeline by Quark Pharmaceuticals, Inc. 160
Table 189: Age Related Macular Degeneration – Pipeline by Ra Pharmaceuticals, Inc. 161
Table 190: Age Related Macular Degeneration – Pipeline by Regeneron Pharmaceuticals, Inc. 161
Table 191: Age Related Macular Degeneration – Pipeline by RegenxBio Inc. 162
Table 192: Age Related Macular Degeneration – Pipeline by Ribomic Inc. 162
Table 193: Age Related Macular Degeneration – Pipeline by RXi Pharmaceuticals Corporation 163
Table 194: Age Related Macular Degeneration – Pipeline by SanBio, Inc. 163
Table 195: Age Related Macular Degeneration – Pipeline by Santen Pharmaceutical Co., Ltd. 164
Table 196: Age Related Macular Degeneration – Pipeline by Sanwa Kagaku Kenkyusho Co., Ltd. 165
Table 197: Age Related Macular Degeneration – Pipeline by SciFluor Life Sciences, LLC 165
Table 198: Age Related Macular Degeneration – Pipeline by Sirnaomics, Inc. 166
Table 199: Age Related Macular Degeneration – Pipeline by Stealth BioTherapeutics Inc. 166
Table 200: Age Related Macular Degeneration – Pipeline by Sucampo Pharmaceuticals, Inc. 167
Table 201: Age Related Macular Degeneration – Pipeline by Sumitomo Dainippon Pharma Co., Ltd. 167
Table 202: Age Related Macular Degeneration – Pipeline by Sun Pharma Advanced Research Company Ltd. 168
Table 203: Age Related Macular Degeneration – Pipeline by TRACON Pharmaceuticals, Inc. 169
Table 204: Age Related Macular Degeneration – Pipeline by TWi Pharmaceuticals, Inc. 170
Table 205: Age Related Macular Degeneration – Pipeline by Tyrogenex, Inc. 170
Table 206: Age Related Macular Degeneration – Pipeline by VasGene Therapeutics, Inc. 171
Table 207: Age Related Macular Degeneration – Pipeline by Wellstat Ophthalmics Corporation 171
Table 208: Age Related Macular Degeneration – Pipeline by Xbrane Biopharma AB 172
Table 209: Diabetic Retinopathy – Pipeline by Acucela Inc. 173
Table 210: Diabetic Retinopathy – Pipeline by Aerie Pharmaceuticals, Inc. 173
Table 211: Diabetic Retinopathy – Pipeline by Aerpio Therapeutics, Inc. 174
Table 212: Diabetic Retinopathy – Pipeline by Antisense Therapeutics Limited 174
Table 213: Diabetic Retinopathy – Pipeline by BCN Peptides, S.A. 175
Table 214: Diabetic Retinopathy – Pipeline by Biomar Microbial Technologies 175
Table 215: Diabetic Retinopathy – Pipeline by Charlesson LLC. 176
Table 216: Diabetic Retinopathy – Pipeline by Coherus BioSciences, Inc. 176
Table 217: Diabetic Retinopathy – Pipeline by Crinetics Pharmaceuticals, Inc. 177
Table 218: Diabetic Retinopathy – Pipeline by Diffusion Pharmaceuticals Inc. 177
Table 219: Diabetic Retinopathy – Pipeline by Dimerix Bioscience Pty Ltd 178
Table 220: Diabetic Retinopathy – Pipeline by Dynamis Therapeutics, Inc. 178
Table 221: Diabetic Retinopathy – Pipeline by EyeGene, Inc. 179
Table 222: Diabetic Retinopathy – Pipeline by Foresee Pharmaceuticals, LLC 179
1.2 List of Figures
Figure 1: Number of Products under Development for Age Related Macular Degeneration 18
Figure 2: Number of Products under Development for Age Related Macular Degeneration – Comparative Analysis 19
Figure 3: Number of Products under Development for Diabetic Retinopathy 20
Figure 4: Number of Products under Development for Diabetic Retinopathy – Comparative Analysis 21
Figure 5: Number of Products under Development for Diabetic Macular Edema 22
Figure 6: Number of Products under Development for Diabetic Macular Edema – Comparative Analysis 23
Figure 7: Number of Products under Development for Keratoconjunctivitis sicca (Dry Eye) 24
Figure 8: Number of Products under Development for Keratoconjunctivitis sicca (Dry Eye) – Comparative Analysis 25
Figure 9: Number of Products under Development for Glaucoma, H2 2016 26
Figure 10: Number of Products under Development for Glaucoma – Comparative Analysis, H2 2016 27
Figure 11: Number of Products under Development by Companies 28
Figure 12: Number of Products under Development by Companies 39
Figure 13: Number of Products under Development by Companies 42
Figure 14: Number of Products under Development by Companies 46
Figure 15: Number of Products under Development by Companies, H2 2016 50
Figure 16: Number of Products under Investigation by Universities/Institutes 56
Figure 17: Number of Products under Investigation by Universities/Institutes 57
Figure 18: Number of Products under Investigation by Universities/Institutes, H2 2016 58
Figure 19: Comparative Analysis by Late Stage Development 60
Figure 20: Comparative Analysis by Clinical Stage Development 61
Figure 21: Comparative Analysis by Early Stage Products 62
Figure 22: Comparative Analysis by Clinical Stage Development 64
Figure 23: Comparative Analysis by Early Stage Products 65
Figure 24: Comparative Analysis by Late Stage Development 66
Figure 25: Comparative Analysis by Clinical Stage Development 67
Figure 26: Comparative Analysis by Early Stage Products 68
Figure 27: Comparative Analysis by Late Stage Development 69
Figure 28: Comparative Analysis by Clinical Stage Development 70
Figure 29: Comparative Analysis by Early Stage Products 71
Figure 30: Comparative Analysis by Late Stage Development, H2 2016 72
Figure 31: Comparative Analysis by Clinical Stage Development, H2 2016 73
Figure 32: Comparative Analysis by Early Stage Products, H2 2016 74
Figure 33: Comparative Analysis by Unknown Stage Development, H2 2016 75
Figure 34: Assessment by Monotherapy Products 290
Figure 35: Number of Products by Top 10 Targets 292
Figure 36: Number of Products by Stage and Top 10 Targets 292
Figure 37: Number of Products by Top 10 Mechanism of Actions 300
Figure 38: Number of Products by Stage and Top 10 Mechanism of Actions 300
Figure 39: Number of Products by Top 10 Routes of Administration 306
Figure 40: Number of Products by Stage and Top 10 Routes of Administration 306
Figure 41: Number of Products by Top 10 Molecule Types 308
Figure 42: Number of Products by Stage and Top 10 Molecule Types 308
Figure 43: Assessment by Monotherapy Products 310
Figure 44: Number of Products by Top 10 Targets 311
Figure 45: Number of Products by Stage and Top 10 Targets 311
Figure 46: Number of Products by Top 10 Mechanism of Actions 315
Figure 47: Number of Products by Stage and Top 10 Mechanism of Actions 315
Figure 48: Number of Products by Top 10 Routes of Administration 319
Figure 49: Number of Products by Stage and Top 10 Routes of Administration 319
Figure 50: Number of Products by Top 10 Molecule Types 321
Figure 51: Number of Products by Stage and Top 10 Molecule Types 321
Figure 52: Assessment by Monotherapy Products 322
Figure 53: Number of Products by Top 10 Targets 324
Figure 54: Number of Products by Stage and Top 10 Targets 324
Figure 55: Number of Products by Top 10 Mechanism of Actions 328
Figure 56: Number of Products by Stage and Top 10 Mechanism of Actions 328
Figure 57: Number of Products by Routes of Administration 331
Figure 58: Number of Products by Stage and Routes of Administration 331
Figure 59: Number of Products by Molecule Types 333
Figure 60: Number of Products by Stage and Molecule Types 333
Figure 61: Assessment by Monotherapy Products 335
Figure 62: Number of Products by Top 10 Targets 336
Figure 63: Number of Products by Stage and Top 10 Targets 336
Figure 64: Number of Products by Top 10 Mechanism of Actions 342
Figure 65: Number of Products by Stage and Top 10 Mechanism of Actions 342
Figure 66: Number of Products by Top 10 Routes of Administration 349
Figure 67: Number of Products by Stage and Top 10 Routes of Administration 349
Figure 68: Number of Products by Molecule Types 351
Figure 69: Number of Products by Stage and Molecule Types 351
Figure 70: Assessment by Monotherapy Products, H2 2016 353
Figure 71: Assessment by Combination Products, H2 2016 354
Figure 72: Number of Products by Top 10 Targets, H2 2016 355
Figure 73: Number of Products by Stage and Top 10 Targets, H2 2016 355
Figure 74: Number of Products by Top 10 Mechanism of Actions, H2 2016 362
Figure 75: Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 362
Figure 76: Number of Products by Top 10 Routes of Administration, H2 2016 369
Figure 77: Number of Products by Stage and Top 10 Routes of Administration, H2 2016 369
Figure 78: Number of Products by Top 10 Molecule Types, H2 2016 371
Figure 79: Number of Products by Stage and Top 10 Molecule Types, H2 2016 371
